Business
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-term fin
About this update from Coloplast A/s Class B
[{"type":"image","alt":"Coloplast A/S","displaySize":"","headline":null,"caption":"Coloplast A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/e8ee650caffe7b5e9474eaac1733b4ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CnHAOjRIde9xT5OfHxnjSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e8ee650caffe7b5e9474eaac1733b4ef","width":300,"height":144}},"lazy":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30.","length":322,"tagName":"p"},{"type":"text","content":"At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-term financial ambition towards 2030.","length":211,"tagName":"p"},{"type":"text","content":"Impact4 financial ambition:Coloplast is committed to accelerating shareholder value creation by delivering organic revenue growth above the market, strong growth in EBIT, improvement in ROIC and strong cash flow generation. From the base financial year of 2024/25, Coloplast aims to deliver the following long-term financial ambitions:","length":336,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Organic revenue growth of 7-8% (5-year CAGR until FY 2029/30)","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Absolute EBIT growth* in line with or above revenue growth over the period","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"ROIC of more than 20% in FY 2029/30, with a linear improvement expected over the period","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":222,"olType":false},{"type":"text","content":"The new financial ambition includes the following key assumptions:","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Market growth in the period is expected to be 4-5%","length":50,"tagName":"p"}]},{"val":[{"type":...